scholarly journals Expression of Kl67 In ER+ PR+ HER2- & ERr- PRr- HER2- Breast Cancer Patients

2019 ◽  
Vol 20 (2) ◽  
pp. 37-41
Author(s):  
Md Hasanuzzaman ◽  
Md Johirul Lslam ◽  
AZM Mostaque Hossain ◽  
Md Rassell ◽  
Md Mafizur Rahman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Duct Cell ◽  
Surgical Oncology ◽  
P Value ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Ki 67 ◽  
Her2 Breast Cancer

Background: Carcinoma of the breast is one of the most common malignancies in women worldwide. Objective: The current study was conducted to evaluate the role of Ki-67 as a prognosticmarker in two definite groups of breast cancer patients (ER+ve, PR+ve, HER-ve& triple negative)in Bangladesh perspective. Methods: Sixty nine female breast cancer patients operated at the surgical oncology departmentof National Institute of Cancer Research & Hospital were selected by non-probabilitysampling method and operated specimens were sent for immunohistochemical study of theER, PR, Her2/neu receptors and Ki-67 protein analysis. Statistical analysis was conductedusing SPSS version 17 for Windows software. P-value 0.05 or less was considered as significant. Result: The mean age of the patients was 46.96 years with SD of± 13.13 years. Histopathologyreports revealed that 94.2% (65/69) were suffering from duct cell carcinoma (DCC) whilelobular varieties were found in 2 cases. Majority of the patients with ER+, PR+ and Ki-67 +vestatus were between 36-50 years of age. But for Her2/neu positive cases most of patientswere above 50 years of age. In Luminal A category cancer patients 69.7% showed positiveKi-67 expression but in case of triple negative cases this percentage was 87.5%. However, thisdifference was not statistically significant. Conclusion: Scores based upon staining of ER, PR, Her2/neu and Ki-67 collectively known asIHC4 which can be used as prognostic markers in breast cancer patients. Journal of Surgical Sciences (2016) Vol. 20 (2) :37-41

The role of Ki-67 in molecular breast cancer classification.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 583-583
Author(s):  
George Stathopoulos ◽  
Nikolaos Malamos ◽  
Christos Markopoulos ◽  
Athanasios Polychronis ◽  
Sotirios Rigatos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Progesterone Receptors ◽  
Molecular Classification ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Her 2

583 Background: The Ki-67 antigen was identified the involvement in early steps of polymerase I-dependent ribosomal RNA synthesis. Although it seems that the protein has an important function in cell division, its exact role is still obscure and there is little published work on its overall function. The aim of the present study is to evaluate the contribution of Ki-67 level in respect of tumor recurrence in molecular classified groups of breast cancer patients. Methods: Breast cancer tumor samples were examined for histological confirmation and for estrogen and progesterone receptors, c-erb-B2 expression, proliferation with Grade and Ki-67. Ki-67 was divided in percentage levels, up to 20 and higher than 20%. Immunohistochemistry and Fluorescence in situ hybridization is described for the results of ER, PR, c-erb-B2, Ki-67 biomarkers. Formaldehyde – fixed breast samples were paraffin wax embedded and processed for paraffin sections. The primary antibodies used were: The monoclinal antibody ID5 (M7047, Dakocytomation, Carpinteria, CA) for the detection of ER, the monoclonal anti-PR antibody 636 was used. For the detection of Ki-67 we used monoclonal mouse anti-human Ki-67 MIB-1. The patients molecular classification was Luminal A, Luminal B, Her-2 subtype and basal cell (triple negative). Results: 847 breast cancer patients were recruited. 291 were group as Luminal A, 228 as Luminal B, 221 Her-2 subtype and 107 triple negative. Follow-up was from 3 years to 15 years since diagnosis. It was found that in Luminal A patients, none had Ki-67 higher than 20% and the recurrence was in 10.65%. In Luminal B, the Ki-67 was higher than 20% in 61% of the patients and recurrence 23.68%. In Her-2 subtype >20% Ki-67 was 78.94%, recurrence 17.19%. In triple negative > 20% Ki-67 was in 68.75% and recurrence in 29.90% of the patients. Conclusions: The data presented here indicate that Ki-67 level may be considered as one of valuable biomarkers in breast cancer patients process and recurrence.

scholarly journals The expression and clinical significance of GADD45A in breast cancer patients

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e5344 ◽  
Author(s):  
Junnan Wang ◽  
Yiran Wang ◽  
Fei Long ◽  
Fengshang Yan ◽  
Ning Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Expression Levels ◽  
Cancer Tissues

BackgroundGrowth arrest and DNA-damage-inducible protein 45 alpha (GADD45A) was previously found to be associated with risk of several kinds of human tumors. Here, we studied the expression and clinical significance of GADD45A in breast cancer.MethodsWe performed an immunohistochemical study of GADD45A protein from 419 breast cancer tissues and 116 adjacent non-neoplastic tissues.ResultsSignificantly high GADD45A expression were observed in breast cancer tissues compared with adjacent non-neoplastic tissues (P < 0.001) and were independently correlative with estrogen receptor negative (P = 0.028) and high Ki-67 index (P < 0.001). Kaplan–Meier survival analysis revealed that patients with high GADD45A expression levels had a worse long-term prognosis in triple negative breast cancer (P = 0.041), but it was not an independent prognostic factor in multivariate analysis (P = 0.058).ConclusionsGADD45A expression levels are significantly correlative with estrogen receptor status and Ki-67 index in human breast cancer. Patients with triple negative breast cancer might be stratified into high risk and low risk groups based on the GADD45A expression levels.

scholarly journals Hubungan Dukungan Keluarga dengan Self Esteem pada Pasien Kanker Payudara di Poliklinik Bedah Onkologi RSUP Sanglah Denpasar

2020 ◽  
Vol 9 (2) ◽  
pp. 181
Author(s):  
Ni luh Putu Mahayani ◽  
Ni Komang Sukraandini ◽  
Ni Wayan Suniyadewi
Keyword(s):  
Breast Cancer ◽  
Family Support ◽  
Cancer Patients ◽  
Surgical Oncology ◽  
Self Esteem ◽  
P Value ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Cross Sectional Design ◽  
The Relationship

AbstractBreast cancer sufferers have a tendency to experience a decrease of self esteem that make  patients shall showing symptoms such as blaming themself for what they experienced. One way to increase self esteem in cancer patients is by increasing family participation through family support. The aim of this study is to determine the relationship between family support and self esteem in breast cancer patients. This study was using cross sectional design. The study was taken place at the Surgical Oncology Polyclinic, found samples of 188 respondents which was selected with a purposive sampling technique.The results showed that the majority of respondents were in the category of moderate self-esteem were 98 respondents (52.1%) and the category of moderate family support were 96 respondents (51.1%). The Rank Spearmen test results shows p value 0,000 (p <ɑ), means there is a relationship between self-esteem and family support in breast cancer patients with r value of 0.566 (positive relationship). It is expected that the family will always support the patient in every process of treatment, whether in the form of physical, psychological or financial support that could increase the patient's self esteem

scholarly journals A cross-sectional study on the pattern of recurrence in carcinoma breast patients based on molecular subtypes

2020 ◽  
Vol 7 (6) ◽  
pp. 1712
Author(s):  
Nitheesh Chalil ◽  
Induchoodan Ponnamma Pillai Sukumaran Nair ◽  
Nizarudeen Aliyarukunju ◽  
Abdul Latheef
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Local Recurrence ◽  
Distant Metastasis ◽  
Triple Negative ◽  
Public Health Issue ◽  
P Value ◽  
Luminal A ◽  
Ki 67 ◽  
Carcinoma Breast

Background: Breast cancer is a major public health issue and it is the leading cause of cancer related death in females worldwide. New insights in the cancer treatment led to considerable improvement in the survival of cancer patients. But metastasis remain an area were all sorts of conventional treatments fails and it is the cause of death of most carcinoma breast patients. In this study we aim to establish a possible link to local recurrence and distant metastasis with different biological subtypes of breast cancer.Methods: One hundred and eighty patients of carcinoma breast patients of carcinoma breast who presented with local recurrence or distant metastasis in the period of January 2018 to March 2019 in Government Medical College, Thiruvananthapuram were included in this study. These data were collected from the hospital records.Results: Local recurrence was most seen in triple negative (50%) subtype followed by HER2 (32.1%) enriched. Local recurrence was least among luminal A (13.8%) with a p value of 0.001. Bone metastasis was the most common type of metastasis and was most seen in luminal A (p=0.001). Triple negative had the maximum CNS metastasis with a p value of 0.003. Liver metastasis was seen mostly in luminal B (26.2%) and A (20.7%) and lung metastasis in triple negative (13.5%) and HER2/neu (10.7%). However, there was no significant association for lung or liver metastasis to any subtype.Conclusions: Biological subtypes of breast cancer classified by immunohistochemical expression of ER, PR, HER2, Ki 67 show different clinicopathological features, recurrence pattern, and survival outcomes.

Is there a survival benefit with adjuvant chemotherapy for patients with stage I (T1N0) triple negative breast cancer?

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11547-e11547
Author(s):  
T. H. Luu ◽  
S. Lau ◽  
R. Nelson ◽  
M. Ottochian ◽  
A. Garcia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Survival Benefit ◽  
Triple Negative ◽  
Stage I ◽  
P Value ◽  
Breast Cancer Patients

e11547 Background: Chemotherapy is the only systemic modality for patients with breast cancer lacking expression of estrogen, progesterone, and HER2 receptors (triple negative), a group comprising 15% of all breast cancers. The majority of such patients present with nodal metastases. The median time to distant recurrence is short: at 2.6 years, and median time to death is 4.2 years. (Dent R, et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence, Clin Cancer Res 2007; 13(15) August, 2007). The benefit from proceeding with adjuvant chemotherapy for ≤2cm, node negative triple negative breast cancer remains undefined. Patients and Methods: A retrospective chart review was conducted to assess the benefit of adjuvant chemotherapy for overall survival for stage I (T1N0) triple-negative breast cancer treated from 1996 to 2006 at City of Hope and USC. ER, PR, and HER2 status (as assessed by fluorescent in-situ hybridization (FISH) or immunohistochemistry) were reviewed and confirmed. Overall survival was defined as time from date of diagnosis to date of death. All patients received standard surgery ± radiation. Results: A total of 100 stage I triple-negative breast cancer patients were identified. The median age at diagnosis was 56 (range 27–91). Of the 100 patients, 59 received adjuvant chemotherapy: 38 received anthracycline-based, 17 received non-anthracycline-based regimens and 4 were unknown. Median length of follow-up was 4.0 years. No difference in overall survival was found in patients who received adjuvant chemotherapy (p-value = 0.94). Similarly, there was no difference between patients who received non-anthracycline-based chemotherapy versus those given anthracycline-based chemotherapy (p-value=0.17). The group of patients who received adjuvant chemotherapy were younger (51.8 y.o versus 61.5 y.o (p=0.0004)) and had larger tumor size (13.6mm versus 10.2mm (p=0.0002)). Lack of statistical significance may be related to the limited sample size. Conclusion: We did not find a statistically survival benefit of adjuvant chemotherapy in 100 triple negative stage I breast cancer patients. Further studies are needed to clarify the role of adjuvant chemotherapy in this group of patients. No significant financial relationships to disclose.

scholarly journals Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology)

Breast Care ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. 248-252 ◽  
Author(s):  
Muhammet A. Kaplan ◽  
Ulku Y. Arslan ◽  
Abdurrahman Işıkdogan ◽  
Faysal Dane ◽  
Berna Oksuzoglu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Molecular Subtype ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Curative Surgery ◽  
Luminal B ◽  
Distant Relapse

Purpose: The aim of the study was to investigate the association between the molecular subtypes and patterns of relapse in breast cancer patients who had undergone curative surgery. Methods: We retrospectively evaluated 1,350 breast cancer patients with relapses after curative surgery between 1998 and 2012 from referral centers in Turkey. Patients were divided into 4 biological subtypes according to immunohistochemistry and grade: triple negative, HER2 overexpressing, luminal A and luminal B. Results: The percentages of patients with luminal A, luminal B, HER2-overexpressing, and triple-negative breast cancer were 32.9% (n = 444), 34.9% (n = 471), 12.0% (n = 162), and 20.2% (n = 273), respectively. The distribution of metastases differed among the subgroups: bone (66.2% and 53.9% in luminal A and B vs. 38.9% in HER2-overexpressing and 45.1% in triple negative, p < 0.001), liver (40.1% in HER2-overexpressing vs. 24.5% in luminal A, 33.5% in luminal B, and 27.5% in triple negative, p < 0.001), lung (41.4% in triple negative and 35.2% in HER2-overexpressing vs. 30.2% and 30.6% in luminal A and B, p = 0.008) and brain (25.3% in HER2-overexpressing and 23.1% in triple negative vs. 10.1% and 15.1% in luminal A and B, p < 0.001). Conclusions: Organ-specific metastasis may depend on the molecular subtype of breast cancer. Tailored strategies against distant metastasis concerning the molecular subtypes in breast cancer should be considered.

Sign in / Sign up

Export Citation Format

Share Document